Dianthus Therapeutics, Inc. (NASDAQ: DNTH) announced the pricing of its upsized public offering of 7,313,582 common shares at $81.00 per share and pre-funded warrants to purchase up to 402,468 shares at $80.999 per warrant.

The clinical-stage biotechnology company expects to receive approximately $625 million in gross proceeds before underwriting discounts, commissions and other expenses, according to a company statement. The offering is scheduled to close on March 12, 2026, subject to customary closing conditions.

The pre-funded warrants carry an exercise price of $0.001 per share and are exercisable immediately. Dianthus has granted underwriters a 30-day option to purchase up to an additional 1,157,407 shares at the public offering price, less underwriting discounts and commissions.

The company plans to use net proceeds to advance clinical and preclinical development activities, commercial readiness activities, working capital and general corporate purposes.

Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair serve as joint book-running managers for the offering. LifeSci Capital acts as the company's financial advisor.

The offering is being conducted under a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on January 30, 2026, and a related registration statement filed on March 10, 2026.

Dianthus develops therapies for severe autoimmune diseases and is based in New York City and Waltham, Massachusetts.